Zacks.com on MSN3d
FDA Expands Exelixis Cabometyx Label for Neuroendocrine TumorsEXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The regulatory body approved Cabometyx for the treatment of adult and pediatric patients 12 ...
Exelixis (EXEL) wins FDA approval for Cabometyx for advanced pancreatic and extra pancreatic neuroendocrine tumors in ...
Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo.
After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors. | ...
The public has a right to know their risk when and if they choose to drink. Such labeling has precedents with that on tobacco ...
The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.
New research indicates GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, ...
MedPage Today on MSN3d
FDA OKs First Drug for Hyperphagia in Prader-Willi SyndromeDiazoxide choline is the first drug indicated for hyperphagia in the rare genetic disorder. Prior to approval, people with ...
Exelixis (EXEL) on Wednesday announced that the Food and Drug Administration has approved cabozantinib, or Cabometyx, for the treatment of ...
Armed with new clinical trial results, Amgen is expanding studies of its KRAS inhibitor Lumakras in pancreatic cancer, as it tries to extend the label for the first-in-class drug beyond its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback